First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

Tomas Pika, Ute Hegenbart, Pavla Flodrova, Bettina Maier, Christoph Kimmich and Stefan O. Schönland
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.